Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations - Discontinued Operations (Details)

v3.8.0.1
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Accrued liabilities   $ 7,092
Liabilities associated with discontinued operations, current   $ 7,092
Lymphoseek sales revenue $ 2,917,213  
Cost of goods sold 364,192  
Gross profit 2,553,021  
Operating expenses of discontinued operation:      
Research and development 283,533  
Selling, general and administrative 820,203  
Total operating expenses 1,103,736  
Income from discontinued operations 1,449,285  
Interest expense (1,718,506)  
Loss before income taxes (269,221)  
Benefit from income taxes 13,360  
Loss from discontinued operations $ (255,861)